News Quantified

AZN – astrazeneca plc - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

China's Licensing Trends Shaping Global Drug Development Analysis Report 2025: Parent Companies Benefitted from Upfront Payments for R&D, Gaining Equity in Novel Chinese Therapeutics [Yahoo! Finance]

Has AstraZeneca's Strong 30% Rally Left Further Upside in 2025? [Yahoo! Finance]

Massive U.S. drug spending gives Trump trade leverage [Globe and Mail, The (Toronto, Canada)]

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]

Form 6-K ASTRAZENECA PLC For: Dec 04

Form 6-K ASTRAZENECA PLC For: Dec 01

Form 6-K ASTRAZENECA PLC For: Dec 01

Form 6-K ASTRAZENECA PLC For: Nov 26

Form 6-K ASTRAZENECA PLC For: Nov 24

Top News Gainers

3/17 AstraZeneca's combo lung cancer treatment fails late-stage study main goal [Reuters (UK)] 8.3%

4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%

3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%

3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%

10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%

7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%

3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%

2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%

3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%

4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%

Top News Decliners

3/7 Amarin Stock Looks Like a Heart-Healthy Buy on the Dip [Yahoo! Finance News] -4.1%

2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%

3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%

3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%

10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%

3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%

12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%

9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%

10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%

8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day